Research and COVID-19

1 - 31 December 2020

 

In memory of our main sponsor, according to his will and thanks to his extraordinary support specifically dedicated to COVID-19, our foundation has been able to support for an amount of 100'000 CHF a project focused on the research of prognostic autoimmune biomarkers related to COVID-19 in patients suffering from inflammatory rheumatic diseases. 

Summary:  Autoantibodies against apolipoprotein A-1 (apoA-1), the main protein of "good cholesterol", are known markers and mediators of cardiovascular disease in many pathologies, but the validation and extension of these results in patients with chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and spondylitis) remain to be demonstrated. In addition, unpublished observations suggest that COVID-19 disease increases anti-apoA-1 IgG levels following a kinetics similar to that of anti-SARS-CoV-2 antibodies, a better understanding of this emerging phenomenon is needed.  Using the largest multicenter cohort available in Switzerland for these diseases (n=2600), the study aims to i) validate on a large scale the prognostic value of anti-apoA-1 IgG for incident cardiovascular complications in rheumatic diseases, and ii) evaluate the impact of COVID-19 infection on anti-apoA-1 IgG levels and their prognostic value in patients with rheumatic diseases. This study will therefore provide new knowledge on the triad linking infectious diseases, humoral autoimmunity and cardiovascular diseases, from the specific perspective of COVID-19. 

More information :  Supported projects